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Abstract
Background: The factors and the mechanism contributing to an increase in cardiac troponin I  
(cTnI) in patients with chest pain, at least one cardiovascular risk factor, and no evidence of 
coronary heart disease remains elusive.
Methods: Excluding patients with acute coronary syndrome and chronic myocardial isch-
emia, we selected 362 consecutive patients with normal coronary angiography or computed 
tomography coronary angiography results or lesions causing < 50% stenosis in any of the 
coronary arteries from January 2012 to June 2015. Using a cut-off value of 0.01 ng/mL, pa-
tients with cTnI levels ≥ 0.01 ng/mL (164 patients) were compared with those with cTnI levels  
< 0.01 ng/mL. Logistic regression analysis was used to evaluate associations between elevated 
cTnI and patient characteristics.
Results: Other than history of diabetes mellitus (DM) (18.90% vs. 8.08%, p = 0.002), the 
characteristics of the patients with and without elevated cTnI levels were similar. History of DM 
predicted elevation of cTnI level (OR 3.34, 95% CI 1.55–7.20, p = 0.002) in logistic regression 
analysis.
Conclusions: In total, 45.30% of patients with chest pain had elevated cTnI levels with  
a mean level of 0.07 ± 0.10 ng/mL. History of DM rather than blood glucose level itself was 
associated with elevated cTnI levels, whereas female gender was protective against increases 
in cTnI levels. (Cardiol J 2016; 23, 2: 149–154)
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Introduction
Chest pain is a common complaint, usually 
a symptom of benign conditions. However, some 
patients with chest pain have serious or life-
threatening diseases such as acute myocardial in-
farction. The detection of cardiac troponin I (cTnI), 
especially by point-of-care testing [1–3], is an 
immediate and effective triage method, not only 
for rapid risk stratification but also for the predic-
tion of prognosis. Usually, coronary angiography 
(CAG) or computed tomography coronary angiog-
raphy (CTCA) is used to establish final diagnosis; 
unfortunately, some patients have non-significant 
stenotic lesions that appear normal on CTCA and 
CAG despite elevated cTnI levels, inconsistent 
with acute coronary syndrome. Diagnosis and 
management in such patients are challenging for 
physicians. We recruited a cohort of such patients 
at the cardiology department of our hospital to 
evaluate the associations between cTnI point-of-
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aim of this study was to provide clinical physicians 
with information to help with the elimination of 
confounding factors and the correct management 
of this specific group of patients.
Methods
Study population and exclusion criteria
The study population comprised all consecu-
tively hospitalized patients with chest pain, aged 
> 18 years and who had at least one cardiovascular 
risk factor, had undergone CAG or CTCA with 
normal results, and had lesions causing < 50% 
stenosis in any one of the coronary arteries on 
CAG or CTCA. All patients were recruited from 
our cardiology department from January 2012 to 
June 2015. The clinicians decided to test cTnI 
levels according to current guidelines [4] within 
24 h after admission using the ReLIA SSJ-2 device 
(Bi-directional Lateral Flow Immunoassay, ReLIA 
Biotechnologies Co. Ltd., Shenzhen, China). The 
professional staff ensured quality control. All col-
lected samples were centrifuged and tested im-
mediately when room temperature was reached. 
A cut-off value of 0.01 ng/mL was used, and patients 
with cTnI levels ≥ 0.01 ng/mL were included in 
the study group; in contrast, patients with cTnI 
levels < 0.01 ng/mL were allocated to the control 
group. Creatinine clearance (CC) was calculated 
using the following formula: (140 – age) × body 
weight (kg) ÷ [0.814 × serum creatinine (μmol/L)] 
(female × 0.85).
Exclusion criteria
Patients with the following were excluded: 
1. Known coronary heart disease (CHD) and 
history of coronary revascularization; 2. Typical 
exertional chest pain; 3. Dynamic changes on elec-
trocardiograms; 4. Dynamic changes in cTnI levels 
(change of ≥ 20% at different times within 3 h to 
6 h after admission); 5. Myocarditis, pericarditis, 
pleuritis, serious cardiac arrhythmias (exception: 
patients who had atrial fibrillation and a ventricular 
rate between 60 to 100 bpm), hypotension, serious 
anemia or infection, pulmonary embolism, serious 
hepatic (liver function – transaminase ≥ 2 times of 
the upper normal limit) or renal (results of renal 
function including CCs were consistent with the 
criteria of chronic kidney disease 2 stage or more) 
dysfunction, malignant tumors, immune system 
disorders, and hypertriglyceridemia (≥ 5 mmol/L).
General characteristics, New York Heart 
Association (NYHA) functional classes, hepatic 
and renal functions, lipid profiles, and blood glu-
cose levels were recorded according to medical 
records. The diagnosis of hypertension, diabetes 
mellitus (DM), valvular heart disease, and car-
diomyopathy was based on standard guidelines 
[5–7]. Biochemical parameters were provided by 
the central laboratory of our hospital. History 
of DM was confirmed if two or more results of 
fasting or postprandial blood glucose tests were 
consistent with DM or if patients had been 
receiving pharmacologic or non-pharmacologic 
treatments for diabetes for at least 1 month 
before admission.
This study protocol was approved by the 
Ethics Committee of the Fifth People’s Hospital 
of Chongqing, and all patients provided written 
informed consent prior to enrollment.
Statistical analysis
Continuous variables were expressed as 
means ± standard deviations (SD), and categori-
cal variables were expressed as frequencies or 
percentages. Independent samples t-tests and c2 
tests were used to analyze differences between 
groups for continuous variables and categorical 
variables, respectively. Logistic regression (c2 and 
Hosmer-Lemeshow tests) was performed to esti-
mate the goodness of fit. Statistical analyses were 
performed with SPSS version 15.0 (SPSS Inc., 
Chicago, IL). For all comparisons, a 2-sided p-value 
of < 0.05 was considered statistically significant. 
When appropriate, 95% confidence intervals (CI) 
were calculated.
Results
Patients with stenotic lesions had more 
cardiovascular risk factors but similar cTnI 
levels compared to patients without lesions
We included a total of 362 patients with 
a mean age of 61.48 ± 10.52 years in the analysis, 
of whom 207 (57.18%) were women and 194 had 
non-significant stenosis on CAG or CTCA (Fig. 1). 
In general, patients with stenosis had cTnI levels 
similar to those in patients without stenosis (0.03 ± 
± 0.07 ng/mL vs. 0.03 ± 0.08 ng/mL, p = 0.73), 
but were older. History of hypertension and DM 
was more prevalent in patients with stenosis. 
Moreover, systolic blood pressure, white blood 
cell (WBC) count, blood glucose level, and NYHA 
functional class at admission were higher and CC 
were lower in patients with stenosis than those 
without (Table 1).
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Comparison of clinical parameters in  
patients with and without increased  
cTnI levels
The elevated cTnI level group included 164 pa-
tients with a mean cTnI level of 0.07 ± 0.10 ng/mL 
(Table 2). There were no differences between the 
two groups with respect to age, sex, history of hy-
pertension, NYHA functional class, blood pressure 
and blood glucose level on admission, WBC count, 
hemoglobin level, blood urea nitrogen level, serum 
creatinine level, CC, lipid level, and the presence 
of stenosis on CAG or CTCA. However, history of 
DM was more prevalent in patients with elevated 
cTnI levels (p < 0.01).
Analysis of correlations between elevated 
cTnI and cardiovascular risk factors
Taking cTnI as a dependent variable and 
all the clinical parameters as independent vari-
ables, binary classification logistic regression was 
performed to analyze the associations between 
elevated cTnI and cardiovascular risk factors 
(Hosmer-Lemeshow goodness of fit test and c2 
Table 1. Comparison of clinical parameters between the patients with and without stenosis.
Patients with stenosis  
(n = 194)
Patients without stenosis 
(n = 168)
P
Age 62.85 ±10.11 59.89 ± 10.80 < 0.01
Sex (female) 112 (57.73%) 95 (56.55%) 0.82
History of hypertension 117 (60.31%) 70 (41.67%) < 0.01
History of DM 34 (17.53%) 13 (7.74%) < 0.01
NYHA functional class: < 0.01
I 161 (82.98%) 127 (75.60%)
II 31 (16.00%) 27 (16.07%)
III 2 (1.03%) 13 (7.74%)
IV 0 (0%) 1 (0.6%)
SBP [mm Hg] 141.56 ± 25.07 134.16 ± 22.33 < 0.01
DBP [mm Hg] 83.21 ± 14.26 80.64 ± 13.18 0.08
HGB [g/L] 133.00 ± 16.61 133.79 ± 16.21 0.65
WBC [×109/L] 6.49 ± 1.94 6.11 ± 1.69 < 0.01
BUN [mmol/L] 5.71 ± 1.72 5.69 ± 1.89 0.92
SCr [μmol/L] 72.74 ± 18.79 70.19 ± 18.20 0.19
CCs [mL/min] 79.17 ± 25.31 85.26 ± 27.15 0.03
TG [mmol/L] 1.64 ± 0.83 1.57 ± 0.89 0.43
LDL [mmol/L] 2.71 ± 0.91 2.69 ± 0.92 0.85
TC [mmol/L] 4.58 ± 1.06 4.54 ± 1.04 0.73
Blood glucose on admission [mmol/L] 6.69 ± 2.36 6.20 ± 1.63 0.02
Percentage of patients with elevation cTnI 54.9 45.1 0.66
DM — diabetes mellitus; NYHA — New York Heart Association functional class; SBP — systolic blood pressure; DBP — diastolic blood pressure; 
HGB — hemoglobin; WBC — white blood cell count; BUN — blood urea nitrogen; SCr — serum creatinine; CCs — creatinine clearances;  
TG — triglyceride; LDL — low-density lipoprotein cholesterol; TC — total cholesterol; cTnI — cardiac troponin I
Figure 1. Comparison of cardiac troponin I (cTnI) levels 
in patients with and without stenosis.
www.cardiologyjournal.org 151
Bin Zhong et al., History of DM is associated with elevated cTcT in patients with chest pain but no CHD
test: 11.17 and p = 0.19, respectively) (Table 3). 
Female gender and history of DM were associ-
ated with elevated cTnI levels in univariate and 
multivariate analyses; moreover, history of DM 
was a risk factor for elevated cTnI levels (odds 
ratio [OR] 3.34, 95% CI 1.55–7.20, p < 0.01). 
In contrast, female gender was a protective factor 
against elevated cTnI levels (OR 0.48, 95% CI 
0.23–0.99, p < 0.05). However, blood glucose level 
itself on admission did not predict elevated cTnI 
levels (OR 0.94, 95% CI = 0.83–1.06, p = 0.31).
Discussion
Regardless of the presence of stenosis, low 
cTnI levels were found in 45.30% of patients with 
chest paint and at least one cardiovascular risk 
factor but no evidence of CHD. Patients with ste-
nosis had more risk factors for CHD. History of 
DM predicted elevated cTnI levels in this cohort, 
while female gender was a protective factor against 
increased cTnI level.
As one of the biomarkers of myocardial dam-
age, increased cTnI level is found in many clinical 
cases without evidence of CHD. To our knowledge, 
this was the first analysis of the correlations be-
tween elevated cTnI level and the characteristics 
of patients with chest pain with at least one risk 
factor but no evidence of CHD on CAG or CTCA. 
Previous studies investigated elevated cTnI levels 
in various cohorts with different stress responses 
such as diabetic ketoacidosis and shock [8–10]. 
However, no studies have included information 
from CAG or CTGA examinations. Al-Mallah et al. 
[11] reported that 26 of 96 patients with elevated 
cTnI levels and diabetic ketoacidosis but no evi-
dence of acute coronary syndrome had higher risks 
of mortality than patients with normal cTnI levels 
during a 2-year follow-up (50.0% vs. 27.1%, HR 2.3, 
95% CI 1.2–4.8, p = 0.02). Mehta et al. [12] found 
that 16 (43%) of 37 patients with septic shock had 
elevated cTnI levels (≥ 0.01 ng/mL). Becattini et 
al. [10] demonstrated that elevated cTnI levels cor-
related with short-term mortality (OR 5.24; 95% CI 
Table 2. Comparison of the clinical parameters of the two groups (with and without elevated cardiac 
troponin I [cTnI] levels).
Group with increased  
cTnI level (n = 164)
Group without increased 
cTnI level (n = 198)
P
Age 61.41 ± 10.14 61.55 ± 10.86 0.90
Sex (female) 104 (63.41%) 103 (52.02%) < 0.05
History of hypertension 91 (55.49%) 96 (48.49%) 0.18
History of DM 31 (18.90%) 16 (8.08%) < 0.01
NYHA functional class: 0.25
I 127 (76.11%) 161 (78.51%)
II 26 (16.81%) 32 (18.18%)
III 10 (6.19%) 5 (3.31%)
IV 1 0
SBP [mm Hg] 138.00 ± 23.11 138.22 ± 24.93 0.93
DBP [mm Hg] 81.86 ± 12.82 82.15 ± 14.61 0.84
HGB [g/L] 131.65 ± 16.24 134.78 ± 16.44 0.07
WBC [×109/L] 6.41 ± 2.00 6.24 ± 1.70 0.38
BUN [mmol/L] 5.74 ± 2.00 5.77 ± 1.62 0.75
SCr [μmol/L] 70.89 ± 18.88 72.11 ± 18.27 0.54
CCs [mL/min] 82.48 ± 26.47 81.60 ± 26.26 0.75
TG [mmol/L] 1.57 ± 0.83 1.64 ± 0.88 0.47
LDL [mmol/L] 2.62 ± 0.84 2.77 ± 0.97 0.13
TC [mmol/L] 4.50 ± 0.99 4.61 ± 1.10 0.32
Blood glucose on admission [mmol/L] 6.49 ± 2.27 6.61 ± 1.89 0.68
Presence of stenosis on CAG or CTCA 90 (54.87%) 104 (52.53%) 0.66
CAG — coronary angiography; CTCA — computed tomography coronary angiography; rest abbreviations as in Table 1.
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Table 3. Logistic regression analysis of elevated cardiac troponin I (cTnI) and clinical parameters.
B SE Wald P Exp (B) 95% confidence interval
Lower Upper
Sex (female) –0.732 0.369 3.939 0.047 0.481 0.234 0.991
Age –0.011 0.017 0.416 0.519 0.989 0.957 1.022
History of hypertension 0.260 0.245 1.132 0.287 1.298 0.803 2.096
History of diabetes 1.205 0.393 9.408 0.002 3.336 1.545 7.203
Stenosis 0.048 0.235 0.042 0.838 1.049 0.662 1.663
NYHA class 0.246 0.219 1.268 0.260 1.279 0.833 1.964
SBP 0.000 0.007 0.000 0.991 1.000 0.985 1.015
DBP –0.002 0.013 0.023 0.881 0.998 0.973 1.024
HGB –0.007 0.009 0.566 0.452 0.993 0.976 1.011
WBC 0.055 0.065 0.702 0.402 1.056 0.929 1.200
Blood glucose –0.062 0.062 1.018 0.313 0.940 0.833 1.060
BUN –0.046 0.072 0.413 0.520 0.955 0.830 1.099
SCr 0.014 0.012 1.402 0.236 1.014 0.991 1.038
TG –0.227 0.153 2.220 0.136 0.797 0.591 1.074
LDL –0.331 0.298 1.235 0.266 0.718 0.401 1.287
TC 0.230 0.267 0.742 0.389 1.259 0.746 2.124
CCs 0.009 0.009 1.196 0.274 1.010 0.993 1.027
Abbreviations as in Table 1.
3.28–8.38) in a meta-analysis. In contrast, based 
on CAG or CTCA results, we demonstrated that in 
patients with < 50% stenosis or normal arteries, 
45.30% patients with no evident stress response 
had elevated cTnI levels. Of these, 65.96% of 
patients with a history of DM had elevated cTnI 
levels. This was a higher rate than previously 
reported, possibly because the patients in this 
analysis had more risk factors than those included 
in the study by Al-Mallah et al. [11]. Moreover, his-
tory of DM was able to predict elevated cTnI levels 
(OR 3.34, p < 0.01) in logistic regression analysis, 
and the risk of elevated cTnI levels in patients 
with a history of DM was 3-times that of normal 
patients. It was interesting that blood glucose level 
at admission could not predict elevated cTnI levels. 
This phenomenon might reflect, at least in part, 
the results of randomized control studies such as 
ACCORD (Cardiovascular Risk in Diabetes trial) 
[13], which demonstrated that intensive control 
of blood glucose level itself does not necessarily 
translate into prognostic benefits other than the 
microvascular benefits in type 2 DM patients. In 
this analysis, this may have been due to the fact 
that blood glucose levels at admission were not 
significantly higher than normal values (6.49 ± 
± 2.27 mmol/L vs. 6.61 ± 1.89 mmol/L), in contrast 
to other studies in which the patients included had 
diabetic ketoacidosis and markedly higher blood 
glucose levels than normal. In the previous study, 
dual effects of hyperglycemia and stress response 
might have contributed to the elevation of cTnI 
levels. Unfortunately, we could not analyze DM 
exclusively due to the limited sample size and 
lack of integrity of the glycosylated hemoglobin 
data available.
Various mechanisms might result in cTnI level 
elevation in patients with DM but no evidence of 
CHD [14–17], such as diabetic cardiomyopathy, 
metabolic disturbance, oxidative stress, diabetic 
microangiopathy, and diabetic nephropathy, although 
the CCs of all patients were similar in this analysis. 
Other possible mechanisms include myocardium 
apoptosis, alteration of myocardium membrane 
permeability, and myocardial hypertrophy. The 
multifactorial and comprehensive effects of cardio-
vascular risk factors were more likely to contribute 
to elevated cTnI levels. It is reasonable to believe 
that aggressive treatment of basal diseases and 
intensive management of all of cardiovascular risk 
factors including DM is particularly beneficial for 
these patients, as no standard guidelines have been 
established and the mechanism of cTnI level eleva-
tion in these patients remains elusive. It is impera-
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tive to study this mechanism in patients with no 
evidence of CHD and normal CAG or CTCA results, 
as such knowledge might be helpful for clinicians in 
managing this specific group of patients.
Lack of random controls and the possibility of 
false negative and positive results for cTnI were 
the main disadvantages of this analysis. Smoking is 
one of the traditional risk factors for atherosclero-
sis, and active smoking and passive smoking have 
similar hazards, we could not do analysis including 
this variable because of difficulty for quantification 
in practice. It is probable that the predictive value 
of the history of DM or other risk factors could be 
improved by analyzing a larger patient cohort. We 
hope that future randomized controlled studies in 
larger cohorts will help confirm these results.
Conclusions
Many patients with chest pain, at least one 
cardiovascular risk factor, and no evidence of CHD 
on CAG or CTCA presented with slightly elevated 
cTnI levels. We found that history of DM was as-
sociated with increased cTnI levels, while female 
gender was a protective factor against increases in 
cTnI level in this specific population.
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